Our research & development

Simon Youlton, Chief Scientific Officer, joined Sinclair in January 2010 to lead a restructured R&D and regulatory team from the Group‟s corporate offices in the UK. Simon immediately embarked on a strategic review of the R&D pipeline which resulted in swift decisions, and project attrition in order to release and refocus resources towards:

a) leveraging the key company assets with the largest commercial potential, such as delmopinol and the „Flamma‟ branded products for burns and woundcare; and

b) identifying and undertaking the first steps in acquiring/licensing new products and near market developments that can not only synergise with Sinclair‟s existing pharmacy and dermatologists distribution channels but provide products with global reach and significant USPs.